TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05780944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced Bottle-Feeding Education
Description: Participants will be asked to review an educational handout that outlines how to implement PBF during bottle-feeding interactions. Participants will then be asked to watch a video that further describes PBF and illustrates how to implement it with a live infant. A trained research assistant will then answer questions, further explain PBF, and demonstrate PBF with a baby doll, using a standardized script

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced Bottle-Feeding Education
Description: Participants will be asked to review an educational handout that outlines how to implement PBF during bottle-feeding interactions. Participants will then be asked to watch a video that further describes PBF and illustrates how to implement it with a live infant. A trained research assistant will then answer questions, further explain PBF, and demonstrate PBF with a baby doll, using a standardized script
Study: NCT06521060

Intervention type: PROCEDURE
Intervention: tru cut biopsy
Description: Proving that preoperative TCB could provide accurate information about the histological nature of the tumor would have great impact for setting an adequate, tailored, oncologically safe treatment approach.
Study: NCT06488586

Intervention type: DRUG
Intervention: Low dose IV Ketamine vs. IN Esketamine
Description: For IV ketamine treatment, ketamine is administered at 0.5mg/kg over 40 minutes. For IN esketamine treatment, esketamine is administered as a nasal spray, two sprays per nostril (56mg total) for the first treatment and three sprays per nostril (84mg) for the rest of the acute series. All treatments are administered at the academic center under the supervision of a mental health care professional. Patients are asked to come fasting at least two hours prior to treatment and to remain resting in the treatment room throughout the dosing session. Throughout each dosing session, blood pressure, oxygen levels, and onset, duration and severity of common side effects are recorded by nursing staff and/or physicians. Patients are discharged after a minimum of 30 minutes post administration, provided that the vital signs return to baseline and that the patient is calm, alert, and oriented.
Study: NCT05669950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG13909
Description: Solution for infusion
Study: NCT04887870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin-Ejfv
Description: Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
Study: NCT06320340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: the patients were performed following five exercises for 20 minutes of treatment session two days a week for the 8 weeks.: (1) the swan-dive vol. I, (2) the swan-dive vol II., (3) breast stroke preparation vol. I, (4) breast stroke preparation vol. II, and (5) swimming vol. II. All the exercises were repeated for the 10 times in a session. Before the exercises, patients were taught and instructed about the five key elements (lateral expansion, centralization, positioning the chest, the shoulder girdle, and the head) of clinical pilates that they should pay attention to while performing the exercises. In addition, verbal and tactile feedbacks were given to patients during all the treatment sessions to maintain the good posture and to perform exercises properly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: the patients were performed following five exercises for 20 minutes of treatment session two days a week for the 8 weeks.: (1) the swan-dive vol. I, (2) the swan-dive vol II., (3) breast stroke preparation vol. I, (4) breast stroke preparation vol. II, and (5) swimming vol. II. All the exercises were repeated for the 10 times in a session. Before the exercises, patients were taught and instructed about the five key elements (lateral expansion, centralization, positioning the chest, the shoulder girdle, and the head) of clinical pilates that they should pay attention to while performing the exercises. In addition, verbal and tactile feedbacks were given to patients during all the treatment sessions to maintain the good posture and to perform exercises properly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Description: Two channels of four-channelled Compex SP Fit-3 (MediCompex SA in Geneva, Switzerland) was used to apply NMES (120 mA, 400 μs, 150 Hz) on lower trapezius and serratus anterior muscles for 20 minutes during exercise.
Study: NCT04887870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
Study: NCT05159752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
Study: NCT06458010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YOLT-101
Description: The IP is administered intravenously at the predetermined dose.
Study: NCT05515432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of BAY3283142 IR (immediate release) tablet
Description: Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of BAY3283142 IR (immediate release) tablet
Description: Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of BAY3283142 IR (immediate release) tablet
Description: Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of BAY3283142 IR (immediate release) tablet
Description: Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of BAY3283142 IR (immediate release) tablet
Description: Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design
Study: NCT05275023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: PD-1 inhibitor will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: PD-1 inhibitor will be administered as IV infusion.
Study: NCT05947149

Intervention type: OTHER
Intervention: questionnaires administration
Description: Enrolled people will be requested to fill in questionnaires. Cohort A affected by head and neck cancer: SF-12, EORTC QLQ-C30, EORTC QLQ-H\&N43, HADS, Brief COPE, BRCS.~Cohort A affected by skull base/brain cancer: SF-12, EORTC QLQ-BN20, HADS, Brief COPE, BRCS.~Cohort B will receive: EORTC QLQ-C30, BRCS, PROFFIT, SF-12, EORTC QLQ-H\&N43.

Intervention type: OTHER
Intervention: questionnaires administration
Description: Enrolled people will be requested to fill in questionnaires. Cohort A affected by head and neck cancer: SF-12, EORTC QLQ-C30, EORTC QLQ-H\&N43, HADS, Brief COPE, BRCS.~Cohort A affected by skull base/brain cancer: SF-12, EORTC QLQ-BN20, HADS, Brief COPE, BRCS.~Cohort B will receive: EORTC QLQ-C30, BRCS, PROFFIT, SF-12, EORTC QLQ-H\&N43.
Study: NCT06567938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: PCI with DES implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: PCI with DES implantation
Study: NCT06568926

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum Ferritin level
Description: follow up to the ferritin level in beta thalaseemia patients on oral chelation therapy
Study: NCT05174078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically-tailored meals
Description: Medically tailored meals delivered to patients' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Produce box and recipes
Description: Weekly produce box and access to recipes via internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
Study: NCT05112679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROPRIO FOOT® by Ossur
Description: Active prostheses like the PROPRIO FOOT® offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and transepidermal water loss measurement to check skin health.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Empower ankle by Ottobock
Description: Active prostheses -such as the Empower ankle offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and trans epidermal water loss measurement to check skin health.
Study: NCT05724316

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: N/A (says not to repeat information here)
Study: NCT06358807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic microfracture with intraoperative local PRP gel injection
Description: Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion.~PRP preparation and local injection:~PRP is harvested using a PRP preparation kit via centrifugation. Fifty milliliters of autologous venous blood are drawn from the patient and processed. Platelet count is measured for quality control. On average 4 ml of (range 3-6) PRP is obtained and mixed with thrombin calcium agent in preparation for PRP gel. PRP gel is administered to the injured area using a blunt and long-tip injector, with direct visualization under arthroscope.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isolated microfracture
Description: Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion.
Study: NCT05808894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extended pancreatic neck transection during laparoscopic pancreaticoduodenectomy
Description: Transect the pancreatic neck at ≥5mm and ≤10mm beyond the left side of the portal vein.
Study: NCT05275023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil
Description: Tenofovir disoproxil film-coated tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil
Description: Tenofovir disoproxil film-coated tablets will be administered orally.
Study: NCT04701658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Description: Administered intravenously.
Study: NCT05783180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™
Description: Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Placebo)
Study: NCT05800522

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral parent or child directed intervention
Description: Control group will include different behavioral interventions that may include caretakers or the target child, and thus may vary in scope and intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Parents - Coping Kids
Description: Intervention group will receive the transdiagnostic parent intervention (SPARCK). SPARCK is designed to include up to 12 sessions with caretakers. If necessary and applicable, children can attend sessions. The starting point for the development of SPARCK has been the Social Interaction Learning model, which represents the behavioral management perspective. In addition, SPARCK consists of empirically supported components based on attachment theory, emotion socialization, CBT, and family accommodation. Thus, content and strategies have been collected from different theories to provide a diverse toolkit tailored to address transdiagnostic problems in families with externalizing, internalizing, and caregiver challenges. SPARCK content and target strategies are tailored to the needs of the families and children, and the manual explains the content and how the target strategies may be tailored and combined.
Study: NCT06031090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine Injection
Description: intravenous Clonidine 0.5 µg/kg diluted in 10ml normal saline 20 minutes before spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron Injection
Description: intravenous 1mg of granisetron diluted in 10ml normal saline 20 minutes before spinal anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 10 mL Injection
Description: intravenous 10 ml normal saline 20 minutes before spinal anesthesia
Study: NCT05545722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: life coaching group with diabetes
Description: Each patient was interviewed once a week. Coaching interviews were conducted one-on-one and in accordance with coaching principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: life coaching group with diabetes
Description: Each patient was interviewed once a week. Coaching interviews were conducted one-on-one and in accordance with coaching principles.
Study: NCT04846569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Theory-based Intervention
Description: The behavioral intervention is a theoretically driven curriculum focused on supporting mothers from pregnancy through postpartum in order to promote sustained HIV treatment adherence. Sessions utilize motivational interviewing and consist of a range of topics including motherhood, preparing for baby, disclosure, HIV education, adherence, birth experiences, support systems, and living positively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care Control
Description: In addition to standard of care, participants receive the first session of the Transition Theory-based Intervention curriculum which focuses on motherhood and preparation for baby but does not discuss the transition from pregnancy to postpartum or the postpartum period.
Study: NCT06076993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BodyKind programme
Description: BodyKind is a four-session, teacher-led, school-based programme for adolescents aged 15-17 years. This programme was developed by a team of international experts in body image and incorporates empirically supported principles of cognitive dissonance (which involves publicly criticising body ideals) and self-compassion (which involves reappraising self-critical evaluations). BodyKind also contains a social activism component that aims to tackle appearance biases, discrimination and racism and promote greater inclusivity and compassion for others.~Programme Outline Lesson 1. Appearance Bias Lesson 2. Self-compassion \& social media Lesson 3. Compassion for others Lesson 4. Becoming agents of change Learning Objectives~* To cultivate skills in awareness, mindfulness, non-judgement, reflection, conscientiousness, compassion~* To decrease levels of body dissatisfaction and self-criticism~* To improve levels of self-compassion, positive body image, psychological wellbeing
Study: NCT05353426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paragastric autonomic neural blockade
Description: Paragastric autonomic neural blockade with Bupivacaine
Study: NCT05813665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlumosbart
Description: Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
Study: NCT06427746

Intervention type: PROCEDURE
Intervention: Standard
Description: Basic ambulance personnel are trained in the application of the CPSS scale in suspected stroke. The CPSS scale is a tool used to quickly assess stroke severity in pre-hospital settings. It is a three-point scale that takes into account the patient's level of consciousness, facial droop, and arm weakness. If a patient with suspected stroke meets certain criteria, they will be coded as having a suspected stroke by the SOREU. These criteria include having one item in three of the CPSS scale, being of adult age, and being independent at home.
Study: NCT05430412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adacolumn
Description: The study will consist of 10 sessions of Adacolumn® treatment (once per week) and a follow-up period (from week 12 to week 40 since study inclusion).
Study: NCT04696796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mediolateral Episiotomy with BasIQ-4 Surgical Knife
Description: Mediolateral episiotomy will be performed with BasIQ-4 Surgical Knife which cuts from distal to the center with inner knife.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mediolateral Episiotomy with Episiotomy Scissors
Description: Mediolateral episiotomy will be made from the central to the distal with episiotomy scissors
Study: NCT05275023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: TAF film-coated tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: TAF film-coated tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: ETV film-coated tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: ETV film-coated tablets will be administered orally.
Study: NCT05425004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
Study: NCT04967521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib will be administered 200mg orally twice a day. Each cycle is 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally twice a day. Each cycle is 28 days.